258 related articles for article (PubMed ID: 27159174)
1. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
Desai AV; Heneghan MB; Li Y; Bunin NJ; Grupp SA; Bagatell R; Seif AE
Bone Marrow Transplant; 2016 Sep; 51(9):1204-10. PubMed ID: 27159174
[TBL] [Abstract][Full Text] [Related]
2. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
Elborai Y; Hafez H; Moussa EA; Hammad M; Hussein H; Lehmann L; Elhaddad A
Pediatr Transplant; 2016 Mar; 20(2):284-9. PubMed ID: 26614402
[TBL] [Abstract][Full Text] [Related]
3. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
Desai AV; Seif AE; Li Y; Getz K; Fisher BT; Huang V; Mante A; Aplenc R; Bagatell R
Pediatr Blood Cancer; 2016 May; 63(5):901-7. PubMed ID: 26797923
[TBL] [Abstract][Full Text] [Related]
4. Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources.
Elzembely MM; Park JR; Riad KF; Sayed HA; Pinto N; Carpenter PA; Baker KS; El-Haddad A
J Glob Oncol; 2018 Sep; 4():1-12. PubMed ID: 30241255
[TBL] [Abstract][Full Text] [Related]
5. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
Desai AV; Li Y; Getz K; Seif AE; Fisher B; Huang V; Aplenc R; Bagatell R
Pediatr Blood Cancer; 2018 Dec; 65(12):e27372. PubMed ID: 30070014
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
7. Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution.
Soni S; Pai V; Gross TG; Ranalli M
Pediatr Transplant; 2014 Mar; 18(2):217-20. PubMed ID: 24341617
[TBL] [Abstract][Full Text] [Related]
8. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [Abstract][Full Text] [Related]
9. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
10. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy for high-risk retinoblastoma: clinical course and outcome of 14 cases in the National Cancer Center, Japan.
Yasui N; Kawamoto H; Fujiwara M; Aihara Y; Ogawa C; Hosono A; Suzuki S
Bone Marrow Transplant; 2015 Feb; 50(2):221-4. PubMed ID: 25437249
[TBL] [Abstract][Full Text] [Related]
12. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.
Proust-Houdemont S; Pasqualini C; Blanchard P; Dufour C; Benhamou E; Goma G; Semeraro M; Raquin MA; Hartmann O; Valteau-Couanet D
Bone Marrow Transplant; 2016 Aug; 51(8):1076-81. PubMed ID: 27042850
[TBL] [Abstract][Full Text] [Related]
13. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM
Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658
[TBL] [Abstract][Full Text] [Related]
14. Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
Kato S; Kubota Y; Watanabe K; Hogetsu K; Arakawa Y; Koh K; Takita J; Hiwatari M
Pediatr Transplant; 2020 Nov; 24(7):e13772. PubMed ID: 32543778
[TBL] [Abstract][Full Text] [Related]
15. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
[TBL] [Abstract][Full Text] [Related]
16. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
17. Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
Abate ME; Paioli A; Cammelli S; Cesari M; Longhi A; Palmerini E; Ferrari S; Carretta E; Picci P; Piscaglia F
Bone Marrow Transplant; 2018 May; 53(5):591-599. PubMed ID: 29335623
[TBL] [Abstract][Full Text] [Related]
18. Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.
Pasqualini C; Dufour C; Goma G; Raquin MA; Lapierre V; Valteau-Couanet D
Bone Marrow Transplant; 2016 Feb; 51(2):227-31. PubMed ID: 26524264
[TBL] [Abstract][Full Text] [Related]
19. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
20. Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant.
Hillier K; Cheng WS; Whittle SB; Krance R; Foster JH
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e569-e574. PubMed ID: 32032244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]